(Q33762409)

29 July 2017

1 reference

title

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research (English)

1 reference

amyotrophic lateral sclerosis

29 July 2017

main subject

1 reference

R G Miller

1

1 reference

29 July 2017

T L Munsat

series ordinal

2

1 reference

29 July 2017

M Swash

series ordinal

3

1 reference

29 July 2017

B R Brooks

series ordinal

4

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Journal of the Neurological Sciences

29 July 2017

published in

1 reference

29 July 2017

volume

169

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

2-12

1 reference

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

The quest for unbiased research: randomized clinical trials and the CONSORT reporting guidelines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Amyotrophic lateral sclerosis. A study of its presentation and prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

The natural history of amyotrophic lateral sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Natural history of amyotrophic lateral sclerosis in a database population Validation of a scoring system and a model for survival prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Motor neuron disease in the province of Turin, Italy, 1966–1980

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Amyotrophic lateral sclerosis. Clinical features and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Survival prediction in sporadic amyotrophic lateral sclerosis. Age and clinical form at onset are independent risk factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Guidelines for the use and performance of quantitative outcome measures in ALS clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2899%2900209-9

10.1016/S0022-510X(99)00209-9

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference